Oligometastatic Prostate Cancer
In this webinar, we review the latest data, approaches and current treatment recommendations for oligometastatic prostate cancer. This webinar reviews methods that physicians can integrate into their clinics to offer their oligometastatic patients the highest level of care.
Target Audience
This activity is designed to meet the interests of radiation oncologists, physicists, radiation dosimetrists, radiation therapists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Describe methods to optimize cure in those with localized or oligometastatic prostate cancer.
- Discuss techniques to mitigate toxicity in the treatment of prostate cancer.
- Utilize more aggressive forms of treatment for oligometastatic prostate cancer.
- Consider the use of salvage therapy for oligometastatic patients.
- Chad Tang, MD, is employed by MD Anderson Cancer Center. Dr. Tang receives honoraria from Diffusion Pharmaceutical, Siemen Healthineer, Lantheus, Telix, Molli Surgical and Boston Scientific. Dr. Tang receives grant/research funding from Merck. Dr. Tang owns copyrights/receives royalties from the Stanford Office of Technology Licensing, Wolters Kluwer and Osler.
- Shauna McVorran, MD, MHSA, is employed by Geisel School of Medicine at Dartmouth and the Dartmouth Cancer Center.
- Bhanu Prasad Venkatesulu, MD, MBBS, is employed by University of Pittsburgh Medical Center. Dr. Venkatesulu receives grant/research funding from Thomas Gore pancreatic cancer and Gateway to cancer research. Dr. Venkatesulu owns stock in ImmunityBio and Spectrum Pharmaceuticals. Dr. Venkatesulu serves as an Education committee member of ASTRO, a task force mentee with ICRP, an Adhoc member of RadOnc questions, and is a consultant on guidelines with the American Radium Society.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.